Sildenafil (Generic): History and Development of the First PDE5 Inhibitor

From Angina Candidate to Accidental Discovery

Sildenafil's origin story begins in Pfizer's research laboratories in Sandwich, Kent, during the late 1980s. A team led by medicinal chemists Simon Campbell, David Roberts, and Nicholas Terrett set out to develop a treatment for angina pectoris and hypertension by targeting the cyclic GMP pathway in vascular smooth muscle [1]. The compound UK-92,480 was designed to inhibit phosphodiesterase type 5 (PDE5), an enzyme that degrades cyclic guanosine monophosphate (cGMP) in blood vessel walls. By blocking PDE5, the researchers hypothesized they could prolong vasodilation and reduce cardiac workload.

Phase I trials in healthy volunteers began in 1991. The drug showed modest effects on blood pressure and some impact on cardiac hemodynamics, but angina relief fell short of expectations. It didn't work well enough for chest pain to justify continued development in that direction. Something else caught investigators' attention.

Male participants in early-phase studies reported an unexpected side effect: penile erections following dosing. Rather than dismiss these reports, Pfizer scientists recognized the pharmacological logic behind them. The corpus cavernosum contains high concentrations of PDE5, and the nitric oxide/cGMP signaling cascade is the primary mediator of penile erection [2]. By 1993, Pfizer had formally redirected the program toward erectile dysfunction, a condition that affected an estimated 30 million American men at the time but had limited pharmacological treatment options [3].

Mechanism of Action: How Sildenafil Works

Sildenafil does not directly cause erection. It amplifies the natural erectile response triggered by sexual stimulation. When a man is sexually aroused, parasympathetic nerve terminals and endothelial cells in the penis release nitric oxide (NO). This NO activates the enzyme guanylate cyclase, which converts GTP to cyclic GMP. The accumulation of cGMP relaxes smooth muscle cells in the corpus cavernosum, allowing blood to flow into the sinusoidal spaces and produce an erection [2].

PDE5 normally breaks down cGMP, terminating the signal. Sildenafil competitively inhibits PDE5 with an IC50 of approximately 3.5 nM, which is roughly 10-fold more selective for PDE5 than for PDE6 (the retinal isoform) and over 80-fold more selective than for PDE1 [4]. This selectivity profile explains both the drug's efficacy and its side effect pattern: the modest cross-reactivity with PDE6 accounts for the transient blue-tinted vision some patients report.

The drug reaches peak plasma concentration in 30 to 120 minutes (median 60 minutes) after oral dosing on an empty stomach. High-fat meals can delay absorption by roughly 60 minutes and reduce peak concentration by 29% [5]. The elimination half-life is 3 to 5 hours, though clinical effect may persist somewhat longer in many patients.

The Key Trial That Changed Urology

The trial that secured FDA approval was the landmark study by Goldstein and colleagues, published in the New England Journal of Medicine in May 1998 [1]. This was a multicenter, double-blind, placebo-controlled trial enrolling 532 men with erectile dysfunction of organic, psychogenic, or mixed etiology. Participants received fixed doses of sildenafil (25, 50, or 100 mg) or placebo, taken approximately one hour before sexual activity over 24 weeks.

Results were striking. At the 100 mg dose, 69% of all attempts at intercourse were successful, compared with 22% in the placebo group. Mean scores on the International Index of Erectile Function (IIEF) erectile function domain increased from a baseline of approximately 15 to 27 (out of 30) in the 100 mg group, versus an increase to 18 in the placebo group (P<0.001). The drug performed across etiologies, including in subgroups with diabetes and post-radical prostatectomy, though response rates were somewhat lower in these populations [1].

Dr. Irwin Goldstein, lead author of the key trial, described the results at the time: "For the first time, we had an oral medication that could reliably restore erectile function in the majority of men, regardless of the underlying cause."

Side effects were dose-dependent and predominantly mild. Headache occurred in 16% of men on 100 mg (vs. 4% placebo), flushing in 10% (vs. 1%), and dyspepsia in 7% (vs. 2%). Abnormal vision, described as a blue color tinge or increased brightness, appeared in 3% at 100 mg [1].

FDA Approval and the Viagra Era

The FDA approved sildenafil citrate tablets (Viagra) on March 27, 1998, under NDA 20-895. It was the first oral phosphodiesterase type 5 inhibitor approved for erectile dysfunction [5]. The approval came just six months after Pfizer submitted the application, reflecting priority review status.

The commercial impact was immediate and enormous. Viagra generated $1 billion in sales within its first year on the market, making it the fastest drug launch in pharmaceutical history at that time [6]. By 2012, annual global Viagra sales exceeded $2 billion. The drug did more than generate revenue. It fundamentally changed how patients and physicians discussed sexual health, reducing stigma around erectile dysfunction and driving millions of men to seek treatment who had previously suffered in silence.

Pfizer also developed sildenafil for pulmonary arterial hypertension (PAH) under the brand name Revatio, which received FDA approval in June 2005 at a 20 mg three-times-daily dose [7]. This application circled back to the drug's original cardiovascular rationale: PDE5 inhibition relaxes pulmonary vascular smooth muscle, reducing pulmonary artery pressure and improving exercise capacity in PAH patients. The SUPER-1 trial (N=278) demonstrated that sildenafil 20 mg three times daily improved 6-minute walk distance by 45 meters compared to placebo (P<0.001) [7].

Patent Expiration and the Generic Era

Pfizer's US composition-of-matter patent for sildenafil (US Patent 5,250,534) expired in June 2013, but a series of legal settlements and additional patents extended effective market exclusivity for the Viagra brand until December 2017 [8]. Teva Pharmaceuticals launched the first authorized generic version on December 11, 2017, under an agreement with Pfizer. Within months, multiple generic manufacturers entered the market.

The economic impact of generics was dramatic. While branded Viagra had retailed for approximately $65 to $80 per tablet, generic sildenafil quickly dropped below $2 per tablet in many pharmacies. According to GoodRx pricing data, by 2020 the average cash price for generic sildenafil 100 mg ranged from $0.50 to $5.00 per tablet depending on quantity and pharmacy [9]. This represented a price reduction exceeding 95% from the branded product's peak pricing.

Generic availability expanded access considerably. An analysis of IQVIA prescription data showed that total sildenafil prescriptions (brand plus generic) increased by over 30% in the two years following generic entry, with the vast majority of new volume attributable to generic formulations [9]. The 20 mg tablet, originally associated with the PAH indication (Revatio), also became widely available in generic form and is sometimes prescribed off-label for ED at adjusted doses, though this practice raises insurance reimbursement and dosing standardization questions.

Sildenafil's Place Among PDE5 Inhibitors

Sildenafil was the first but not the last PDE5 inhibitor. Tadalafil (Cialis, approved 2003) and vardenafil (Levitra, approved 2003) followed, each with distinct pharmacokinetic profiles. Avanafil (Stendra, approved 2012) joined the class with claims of faster onset [10].

The key differentiator among these agents is duration of action. Sildenafil's half-life of 3 to 5 hours gives it a practical window of 4 to 6 hours. Tadalafil's 17.5-hour half-life supports a 36-hour window, along with a daily low-dose option (2.5 or 5 mg) that maintains steady-state drug levels [10]. Head-to-head data comparing PDE5 inhibitors are limited, but a Cochrane systematic review found no consistent differences in efficacy among the four approved agents when used at recommended doses [11]. Patient preference often dictates choice: men who prefer spontaneity may favor tadalafil's longer window, while men who want a shorter-acting agent with decades of safety data often remain on sildenafil.

Generic sildenafil's cost advantage is substantial even compared to generic tadalafil. As of 2024, sildenafil 100 mg generic tablets remain among the least expensive branded-to-generic ED treatments, which explains its continued dominance in prescription volume. According to ClinCalc, sildenafil ranked as the 97th most prescribed medication in the United States in 2022, with over 28 million prescriptions filled [9].

Safety Profile After 25+ Years of Post-Marketing Data

The FDA's post-marketing surveillance database contains over two decades of real-world safety data on sildenafil, providing an unusually long track record for a medication. The labeled contraindication against concurrent nitrate use remains the most clinically significant safety concern. Co-administration of sildenafil with organic nitrates (nitroglycerin, isosorbide mononitrate or dinitrate) can produce severe, potentially fatal hypotension due to additive effects on the NO/cGMP pathway [5].

The cardiovascular safety of PDE5 inhibitors in men with stable coronary artery disease has been well-established. The Princeton III Consensus Guidelines classify PDE5 inhibitors as safe in men at low cardiovascular risk and recommend exercise stress testing for intermediate-risk patients before prescribing [12]. A 2014 meta-analysis published in the Journal of Sexual Medicine, pooling data from 57 randomized controlled trials (N=20,325), found no increase in myocardial infarction or cardiovascular mortality with PDE5 inhibitor use compared to placebo [13].

Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported in temporal association with PDE5 inhibitor use, though a causal relationship remains unproven. The FDA added NAION to the Viagra label as a precaution in 2005, and a subsequent case-crossover study estimated an odds ratio of 2.15 (95% CI 1.06 to 4.34) for NAION within five half-lives of PDE5 inhibitor use [14]. Men with a history of NAION in one eye should be counseled about theoretical risk before initiating therapy. Sudden sensorineural hearing loss has also been reported rarely, prompting a 2007 label update [5].

The Development Pipeline That Sildenafil Built

Sildenafil's commercial success catalyzed an entire therapeutic area. Before 1998, pharmacological ED treatment consisted primarily of intracavernosal injections (alprostadil), intraurethral suppositories (MUSE), and vacuum erection devices. Oral therapy transformed the field. The drug's success also accelerated research into the broader biology of PDE5, leading to the PAH indication, investigations in heart failure with preserved ejection fraction (HFpEF), Raynaud phenomenon, and even altitude sickness [15].

A 2020 retrospective cohort study published in JAMA Cardiology, analyzing data from over 200,000 men with type 2 diabetes in the UK, found that PDE5 inhibitor use was associated with a 19% lower risk of major adverse cardiovascular events (HR 0.81 to 95% CI 0.76 to 0.87) and a 25% lower risk of all-cause mortality compared to non-users [16]. These observational findings do not prove causation, but they have generated interest in prospective trials of PDE5 inhibitors for cardiovascular protection.

The sildenafil story also reshaped pharmaceutical strategy. The "failed" angina program that became the most commercially successful drug launch in history demonstrated the value of serendipity in drug development, and the importance of researchers who pay attention to unexpected findings rather than discarding them as noise.

Current Prescribing and Access

Generic sildenafil is available in 20 mg, 25 mg, 50 mg, and 100 mg tablets. The standard starting dose for ED is 50 mg taken approximately one hour before sexual activity, with dose adjustment to 25 or 100 mg based on efficacy and tolerability [5]. Maximum recommended frequency is once daily. The 20 mg strength (generic Revatio) is FDA-approved specifically for PAH at 20 mg three times daily.

Telehealth platforms have further expanded sildenafil access since 2020. Prescriptions obtained through telehealth encounters now account for a measurable share of total PDE5 inhibitor prescriptions, particularly among men aged 25 to 44 who may be less likely to raise the topic with an in-person physician [9]. Generic sildenafil's low cost and established safety profile make it a common first-line recommendation in clinical guidelines, including the American Urological Association's 2018 guideline on erectile dysfunction, which recommends PDE5 inhibitors as first-line pharmacotherapy for most men with ED [17].

Men taking alpha-blockers for benign prostatic hyperplasia should begin sildenafil at 25 mg due to potential additive hypotension. Dose reduction to 25 mg is also recommended for patients over 65, those with hepatic impairment (Child-Pugh A or B), those with severe renal impairment (creatinine clearance <30 mL/min), and patients on moderate CYP3A4 inhibitors such as erythromycin [5].